115 related articles for article (PubMed ID: 38307818)
21. A population-based competing-risks analysis of survival after nephrectomy for renal cell carcinoma.
Bianchi M; Gandaglia G; Trinh QD; Hansen J; Becker A; Abdollah F; Tian Z; Lughezzani G; Roghmann F; Briganti A; Montorsi F; Karakiewicz PI; Sun M
Urol Oncol; 2014 Jan; 32(1):46.e1-7. PubMed ID: 24054864
[TBL] [Abstract][Full Text] [Related]
22. Contemporary vs historical survival rates in metastatic clear cell renal carcinoma according to race/ethnicity.
Sorce G; Hoeh B; Hohenhorst L; Panunzio A; Tappero S; Nimer N; Tian Z; Larcher A; Capitanio U; Tilki D; Terrone C; Chun FKH; Antonelli A; Saad F; Shariat SF; Montorsi F; Briganti A; Karakiewicz PI
World J Urol; 2022 Dec; 40(12):2971-2978. PubMed ID: 36222885
[TBL] [Abstract][Full Text] [Related]
23. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.
Bhindi B; Abel EJ; Albiges L; Bensalah K; Boorjian SA; Daneshmand S; Karam JA; Mason RJ; Powles T; Bex A
Eur Urol; 2019 Jan; 75(1):111-128. PubMed ID: 30467042
[TBL] [Abstract][Full Text] [Related]
24. Partial vs. radical nephrectomy in non-metastatic pT3a kidney cancer patients: a population-based study.
Pecoraro A; Amparore D; Manfredi M; Piramide F; Checcucci E; Tian Z; Peretti D; Fiori C; Karakiewicz PI; Porpiglia F
Minerva Urol Nephrol; 2022 Aug; 74(4):445-451. PubMed ID: 35147387
[TBL] [Abstract][Full Text] [Related]
25. Assessment of local tumor ablation and non-interventional management versus partial nephrectomy in T1a renal cell carcinoma.
Palumbo C; Mistretta FA; Knipper S; Mazzone E; Pecoraro A; Tian Z; Perrotte P; Antonelli A; Montorsi F; Shariat SF; Saad F; Simeone C; Briganti A; Lavallee LT; Karakiewicz PI
Minerva Urol Nefrol; 2020 Jun; 72(3):350-359. PubMed ID: 31487976
[TBL] [Abstract][Full Text] [Related]
26. Comparison of oncologic outcomes between sarcomatoid and clear cell renal cell carcinoma.
Trudeau V; Larcher A; Sun M; Boehm K; Dell'Oglio P; Sosa J; Tian Z; Fossati N; Briganti A; Shariat SF; Karakiewicz PI
World J Urol; 2016 Oct; 34(10):1429-36. PubMed ID: 26902877
[TBL] [Abstract][Full Text] [Related]
27. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma.
Bhindi B; Graham J; Wells JC; Bakouny Z; Donskov F; Fraccon A; Pasini F; Lee JL; Basappa NS; Hansen A; Kollmannsberger CK; Kanesvaran R; Yuasa T; Ernst DS; Srinivas S; Rini BI; Bowman I; Pal SK; Choueiri TK; Heng DYC
Eur Urol; 2020 Oct; 78(4):615-623. PubMed ID: 32362493
[TBL] [Abstract][Full Text] [Related]
28. Cryoablation Predisposes to Higher Cancer Specific Mortality Relative to Partial Nephrectomy in Patients with Nonmetastatic pT1b Kidney Cancer.
Pecoraro A; Palumbo C; Knipper S; Mistretta FA; Tian Z; Shariat SF; Saad F; Briganti A; Fiori C; Porpiglia F; Karakiewicz PI
J Urol; 2019 Dec; 202(6):1120-1126. PubMed ID: 31347950
[TBL] [Abstract][Full Text] [Related]
29. Unmarried status is a barrier for access to treatment in patients with metastatic renal cell carcinoma.
Rosiello G; Knipper S; Palumbo C; Dzyuba-Negrean C; Pecoraro A; Mazzone E; Mistretta FA; Tian Z; Capitanio U; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
Int Urol Nephrol; 2019 Dec; 51(12):2181-2188. PubMed ID: 31468289
[TBL] [Abstract][Full Text] [Related]
30. Impact of Tumor Size on Cancer-Specific Mortality Rate After Local Tumor Ablation in T1a Renal-Cell Carcinoma.
Palumbo C; Cyr SJ; Mazzone E; Mistretta FA; Knipper S; Pecoraro A; Tian Z; Shariat SF; Saad F; Simeone C; Briganti A; Kapoor A; Antonelli A; Karakiewicz PI
J Endourol; 2019 Jul; 33(7):606-613. PubMed ID: 30990074
[No Abstract] [Full Text] [Related]
31. Outcomes of Cytoreductive Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Real World Data from Canadian Centers.
Dragomir A; Nazha S; Tanguay S; Breau RH; Bhindi B; Rendon RA; Kapoor A; Hotte SJ; Basappa N; Fairey A; So AI; Kollmannsberger C; Finelli A; Hansen A; Canil C; Heng D; Lattouf JB; Bjarnason G; Power N; Pouliot F; Wood LA
Eur Urol Focus; 2022 Nov; 8(6):1703-1710. PubMed ID: 34736870
[TBL] [Abstract][Full Text] [Related]
32. The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: A Real-World Multi-Institutional Analysis.
Ghatalia P; Handorf EA; Geynisman DM; Deng M; Zibelman MR; Abbosh P; Anari F; Greenberg RE; Viterbo R; Chen D; Smaldone MC; Kutikov A; Uzzo RG
J Urol; 2022 Jul; 208(1):71-79. PubMed ID: 35212574
[TBL] [Abstract][Full Text] [Related]
33. A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomy.
Gross EE; Li M; Yin M; Orcutt D; Hussey D; Trott E; Holt SK; Dwyer ER; Kramer J; Oliva K; Gore JL; Schade GR; Lin DW; Tykodi SS; Hall ET; Thompson JA; Parikh A; Yang Y; Collier KA; Miah A; Mori-Vogt S; Hinkley M; Mortazavi A; Monk P; Folefac E; Clinton SK; Psutka SP
Urol Oncol; 2023 Jan; 41(1):51.e25-51.e31. PubMed ID: 36441070
[TBL] [Abstract][Full Text] [Related]
34. Cytoreductive nephrectomy in metastatic renal cell carcinoma: outcome of patients treated with a multidisciplinary, algorithm-driven approach.
Liu WK; Lam JM; Butters T; Grant M; Jackson-Spence F; Bex A; Powles T; Szabados B
World J Urol; 2020 Dec; 38(12):3199-3205. PubMed ID: 32128610
[TBL] [Abstract][Full Text] [Related]
35. Non-cancer mortality in elderly prostate cancer patients treated with combination of radical prostatectomy and external beam radiation therapy.
Wenzel M; Würnschimmel C; Chierigo F; Tian Z; Shariat SF; Terrone C; Saad F; Tilki D; Graefen M; Mandel P; Kluth LA; Chun FKH; Karakiewicz PI
Prostate; 2021 Aug; 81(11):728-735. PubMed ID: 34010465
[TBL] [Abstract][Full Text] [Related]
36. Comparison of survival outcomes in patients with metastatic papillary vs. clear-cell renal cell carcinoma: a propensity-score analysis.
Rosiello G; Palumbo C; Knipper S; Pecoraro A; Luzzago S; St-Hilaire PA; Tian Z; Capitanio U; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
World J Urol; 2021 Feb; 39(2):461-472. PubMed ID: 32253579
[TBL] [Abstract][Full Text] [Related]
37. Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities.
Würnschimmel C; Wenzel M; Collà Ruvolo C; Nocera L; Tian Z; Saad F; Briganti A; Shariat SF; Mandel P; Chun FKH; Tilki D; Graefen M; Karakiewicz PI
World J Urol; 2021 Oct; 39(10):3781-3787. PubMed ID: 33978812
[TBL] [Abstract][Full Text] [Related]
38. Other-cause mortality in incidental prostate cancer.
Di Bello F; Baudo A; de Angelis M; Jannello LMI; Siech C; Tian Z; Goyal JA; Collà Ruvolo C; Califano G; La Rocca R; Morra S; Acquati P; Saad F; Shariat SF; Carmignani L; de Cobelli O; Briganti A; Chun FKH; Longo N; Karakiewicz PI
Prostate; 2024 Jun; 84(8):731-737. PubMed ID: 38506561
[TBL] [Abstract][Full Text] [Related]
39. Metastatic renal cell carcinoma patients of T4 stage who are in status of N1 stage or older than 76 years cannot benefit from cytoreductive nephrectomy.
Zhang Z; Wu H; Yang T; Wu Y; Yu N; Xu Z
BMC Cancer; 2020 Sep; 20(1):844. PubMed ID: 32883242
[TBL] [Abstract][Full Text] [Related]
40. Assessment of survival of patients with metastatic clear cell renal cell carcinoma after radical cytoreductive nephrectomy versus no surgery: a seer analysis.
Xiao WJ; Zhu Y; Dai B; Zhang HL; Ye DW
Int Braz J Urol; 2015; 41(2):288-95. PubMed ID: 26005970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
